JosÃ© Ãngel MartÃ-nez-Climent

List of Publications by Year
in descending order

106 papers	5,558 citations	61984 43 h-index	82547 72 g-index
107 all docs	107 docs citations	107 times ranked	9988 citing authors

#	Article	IF	Citations
1	The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, encoding a new member of the AP-3 clathrin assembly protein family.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 4804-4809.	7.1	277
2	MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL InÂVitro and InÂVivo. Cancer Cell, 2012, 22, 812-824.	16.8	229
3	Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood, 2007, 109, 271-280.	1.4	227
4	Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood, 2003, 101, 3109-3117.	1.4	212
5	MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood, 2003, 101, 4539-4546.	1.4	188
6	Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood, 2005, 105, 4445-4454.	1.4	180
7	Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood, 2014, 123, 4111-4119.	1.4	161
8	KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. Leukemia, 2015, 29, 1177-1185.	7.2	156
9	Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. Blood, 2005, 106, 3214-3222.	1.4	137
10	The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Research, 2003, 63, 8226-32.	0.9	130
11	Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood, 2003, 101, 4042-4046.	1.4	121
12	Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. Human Molecular Genetics, 2004, 13, 1827-1837.	2.9	115
13	BCR-ABL Induces the Expression of Skp2 through the PI3K Pathway to Promote p27Kip1 Degradation and Proliferation of Chronic Myelogenous Leukemia Cells. Cancer Research, 2005, 65, 3264-3272.	0.9	111
14	Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. Nature Communications, 2017, 8, 15424.	12.8	109
15	C/EBPÎ± Induces Highly Efficient Macrophage Transdifferentiation of B Lymphoma and Leukemia Cell Lines and Impairs Their Tumorigenicity. Cell Reports, 2013, 3, 1153-1163.	6.4	99
16	Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood, 2010, 116, 2531-2542.	1.4	96
17	The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nature Communications, 2019, 10, 2235.	12.8	96
18	Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis. Oncogene, 2009, 28, 1892-1903.	5.9	94

#	Article	IF	Citations
19	Novel Genomic Imbalances in B-Cell Splenic Marginal Zone Lymphomas Revealed by Comparative Genomic Hybridization and Cytogenetics. American Journal of Pathology, 2001, 158, 1843-1850.	3.8	88
20	Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma. Blood, 2001, 98, 3479-3482.	1.4	86
21	Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci. International Journal of Cancer, 2002, 98, 470-474.	5.1	84
22	PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. Blood, 2011, 118, 5517-5527.	1.4	83
23	Cellular Plasticity Confers Migratory and Invasive Advantages to a Population of Glioblastoma-Initiating Cells that Infiltrate Peritumoral Tissue. Stem Cells, 2013, 31, 1075-1085.	3.2	83
24	Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. Blood, 2021, 137, 49-60.	1.4	80
25	Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study. Leukemia, 2003, 17, 2016-2024.	7.2	76
26	Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. European Journal of Cancer, 2009, 45, 1877-1889.	2.8	76
27	Deletion of Chromosome 11q Predicts Response to Anthracycline-Based Chemotherapy in Early Breast Cancer. Cancer Research, 2007, 67, 818-826.	0.9	75
28	Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 10534-10539.	7.1	73
29	Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. Nature Communications, 2014, 5, 3904.	12.8	73
30	Blockade of the NFÎºB pathway drives differentiating glioblastoma-initiating cells into senescence both in vitro and in vivo. Oncogene, 2011, 30, 3537-3548.	5.9	69
31	Epigenetic regulation of miRNA genes in acute leukemia. Leukemia, 2012, 26, 395-403.	7.2	66
32	Involvement of miRNAs in the Differentiation of Human Glioblastoma Multiforme Stem-Like Cells. PLoS ONE, 2013, 8, e77098.	2.5	64
33	Downregulation of FOXP1 is required during germinal center B-cell function. Blood, 2013, 121, 4311-4320.	1.4	62
34	Identification and molecular characterization of CALM/AF10fusion products in T cell acute lymphoblastic leukemia and acute myeloid leukemia. Leukemia, 2000, 14, 100-104.	7.2	60
35	Molecular cytogenetics of childhood hematological malignancies. Leukemia, 1997, 11, 1999-2021.	7.2	58
36	Lymphoma stem cells: enough evidence to support their existence?. Haematologica, 2010, 95, 293-302.	3.5	57

#	Article	IF	Citations
37	PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. Blood, 2019, 133, 2401-2412.	1.4	54
38	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. Blood, 2015, 125, 1922-1931.	1.4	53
39	Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14)(q24.1q32.33). Leukemia, 2009, 23, 2153-2155.	7.2	50
40	A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12461-12466.	7.1	50
41	Abnormalities of Chromosome Band 11q23 and the MLL Gene in Pediatric Myelomonocytic and Monoblastic Leukemias. Journal of Pediatric Hematology/Oncology, 1995, 17, 277-283.	0.6	49
42	Somatic stem cells and the origin of cancer. Clinical and Translational Oncology, 2006, 8, 647-663.	2.4	49
43	ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA. Oncogene, 2017, 36, 1733-1744.	5.9	48
44	Highâ€throughput sequencing analysis of the chromosome 7q32 deletion reveals <scp>IRF</scp>5 as a potential tumour suppressor in splenic marginalâ€zone lymphoma. British Journal of Haematology, 2012, 158, 712-726.	2.5	45
45	Deregulation of the telomerase reverse transcriptase (TERT) gene by chromosomal translocations in B-cell malignancies. Blood, 2010, 116, 1317-1320.	1.4	44
46	Detection of translocations affecting the BCL6 locus in B cell non-Hodgkin's lymphoma by interphase fluorescence in situ hybridization. Leukemia, 2001, 15, 1475-1484.	7.2	42
47	Partial uniparental disomy: a recurrent genetic mechanism alternative to chromosomal deletion in malignant lymphoma. Leukemia, 2006, 20, 904-905.	7.2	42
48	Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics. Nature Communications, 2016, 7, 11889.	12.8	42
49	Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death. Cancer Discovery, 2021, 11, 1268-1285.	9.4	42
50	Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. Leukemia, 2012, 26, 1517-1526.	7.2	41
51	Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma. Blood, 2012, 119, 5478-5491.	1.4	39
52	<scp>LITAF</scp>, a <scp>BCL</scp>6 target gene, regulates autophagy in mature Bâ€cell lymphomas. British Journal of Haematology, 2013, 162, 621-630.	2.5	39
53	Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation. Nature Communications, 2013, 4, 1338.	12.8	37
54	Analysis of translocations that involve theNUP98 gene in patients with 11p15 chromosomal rearrangements. Genes Chromosomes and Cancer, 2004, 41, 339-352.	2.8	36

#	Article	IF	Citations
55	Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy. Journal of Medicinal Chemistry, 2018, 61, 6518-6545.	6.4	36
56	Homozygous deletion of SOCS1 in primary mediastinal B-cell lymphoma detected by CGH to BAC microarrays. Leukemia, 2005, 19, 1082-1084.	7.2	35
57	Identified hidden genomic changes in mantle cell lymphoma using high-resolution single nucleotide polymorphism genomic array. Experimental Hematology, 2009, 37, 937-946.	0.4	35
58	The BCL6 gene in B-cell lymphomas with 3q27 translocations is expressed mainly from the rearranged allele irrespective of the partner gene. Leukemia, 2003, 17, 1390-1397.	7.2	32
59	Genetic diagnosis by comparative genomic hybridization in adult de novo acute myelocytic leukemia. Cancer Genetics and Cytogenetics, 2004, 153, 16-25.	1.0	29
60	GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma. British Journal of Haematology, 2009, 144, 317-331.	2.5	28
61	Chromosomal Rearrangements in Childhood Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of Pediatric Hematology/Oncology, 1999, 21, 91-102.	0.6	26
62	LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome. Haematologica, 2011, 96, 980-986.	3.5	26
63	Cytogenetic response induced by interferon alpha in the myeloproliferative disorder with eosinophilia, T cell lymphoma and the chromosomal translocation t(8;13)(p11;q12). Leukemia, 1998, 12, 999-1000.	7.2	24
64	Genomic Abnormalities Acquired in the Blastic Transformation of Splenic Marginal Zone B-cell Lymphoma. Leukemia and Lymphoma, 2003, 44, 459-464.	1.3	24
65	Richter transformation driven by Epsteinâ€"Barr virus reactivation during therapyâ€"related immunosuppression in chronic lymphocytic leukaemia. Journal of Pathology, 2018, 245, 61-73.	4.5	24
66	Frequent mutations in the amino-terminal domain of BCL7A impair its tumor suppressor role in DLBCL. Leukemia, 2020, 34, 2722-2735.	7.2	24
67	Expression profiles of adult T-cell leukemiaâ€"lymphoma and associations with clinical responses to zidovudine and interferon Î±. Leukemia and Lymphoma, 2010, 51, 1200-1216.	1.3	23
68	Molecular Characterization of the Region 7q22.1 in Splenic Marginal Zone Lymphomas. PLoS ONE, 2011, 6, e24939.	2.5	23
69	Soluble intercellular adhesion molecule-1 (s-ICAM-1/s-CD54) in diffuse large B-cell lymphoma: association with clinical characteristics and outcome. Annals of Oncology, 2003, 14, 467-474.	1.2	22
70	Preneoplastic somatic mutations including MYD88 ^{L265P} in lymphoplasmacytic lymphoma. Science Advances, 2022, 8, eabl4644.	10.3	21
71	Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces. Journal of Medicinal Chemistry, 2018, 61, 6546-6573.	6.4	19
72	Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome. Bone Marrow Transplantation, 2000, 25, 1203-1208.	2.4	18

#	Article	IF	Citations
73	Scale for assessing quality of life of children survivors of cranial posterior fossa tumors. Journal of Neuro-Oncology, 1994, 22, 67-76.	2.9	17
74	Recurrent loss of the Y chromosome and homozygous deletions within the pseudoautosomal region 1: association with male predominance in mantle cell lymphoma. Haematologica, 2008, 93, 949-950.	3.5	17
75	Bcl-6 mutation status provides clinically valuable information in early-stage B-cell chronic lymphocytic leukemia. Leukemia, 2004, 18, 743-746.	7.2	16
76	Intrinsic resistance to PIM kinase inhibition in AML through p38Î±-mediated feedback activation of mTOR signaling. Oncotarget, 2016, 7, 37407-37419.	1.8	16
77	Molecular analysis of the Mono Mac 6 cell line: detection of an MLL-AF9 fusion transcript [letter; comment]. Blood, 1995, 85, 855-856.	1.4	15
78	Identification of two subgroups of mantle cell leukemia with distinct clinical and biological features. The Hematology Journal, 2001, 2, 234-241.	1.4	15
79	A quantitative analysis of genomic instability in lymphoid and plasma cell neoplasms based on the PIG-A gene. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2010, 686, 1-8.	1.0	13
80	B-cell leukemia transdifferentiation to macrophage involves reconfiguration of DNA methylation for long-range regulation. Leukemia, 2020, 34, 1158-1162.	7.2	13
81	Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations. BMC Genomics, 2015, 16, 752.	2.8	12
82	Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasms. Haematologica, 2018, 103, 1065-1072.	3.5	10
83	Variant Three-Way Translocation of Inversion 16 in AML-M4Eo Confirmed by Fluorescence In Situ Hybridization Analysis. Cancer Genetics and Cytogenetics, 1999, 110, 111-114.	1.0	9
84	Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation. British Journal of Haematology, 2003, 120, 500-504.	2.5	9
85	The origin and targeting of mucosa-associated lymphoid tissue lymphomas. Current Opinion in Hematology, 2014, 21, 309-319.	2.5	9
86	MALT lymphoma meets stem cells. Cell Cycle, 2012, 11, 2961-2962.	2.6	7
87	Lineage-specific function of Engrailed-2 in the progression of chronic myelogenous leukemia to T-cell blast crisis. Cell Cycle, 2014, 13, 1717-1726.	2.6	7
88	Non-Malignant Tumors that Can Mimic Cancer During the Neonatal Period. European Journal of Pediatric Surgery, 1995, 5, 156-159.	1.3	5
89	Divergence of Vascular Specification in Visceral Lymphoid Organsâ€"Genetic Determinants and Differentiation Checkpoints. International Reviews of Immunology, 2016, 35, 489-502.	3.3	5
90	CLL intraclonal fractions exhibit established and recently acquired patterns of DNA methylation. Blood Advances, 2020, 4, 893-905.	5.2	5

#	Article	IF	Citations
91	Integrative Oncogenomic Analysis of Microarray Data in Hematologic Malignancies. Methods in Molecular Biology, 2009, 576, 231-277.	0.9	5
92	G-protein coupled receptor (GPCR) mutations in lymphoid malignancies: linking immune signaling activation and genetic abnormalities. Haematologica, 2018, 103, 1252-1255.	3.5	4
93	Acute lymphoblastic leukaemia in a child with hereditary spherocytosis. European Journal of Pediatrics, 1995, 154, 753-754.	2.7	3
94	Generation of a New Monoclonal Antibody Against MALT1 by Genetic Immunization. Hybridoma, 2007, 26, 86-91.	0.4	3
95	Genomic Profiling of Mantle Cell Lymphoma. Methods in Molecular Biology, 2013, 973, 147-163.	0.9	3
96	Pediatricians and Cancer Prevention. JAMA Pediatrics, 1997, 151, 209.	3.0	2
97	Epigenetic Silencing of BIM Mediates Chemotherapy Resistance of Patients with Burkitt Lymphoma That Can Be Overcome by Therapeutic Reactivation of BIM in Mouse and Human Lymphoma Models. Blood, 2008, 112, 607-607.	1.4	2
98	Inhibition of the Methyltransferase G9a with Small Molecules As a New Therapeutic Strategy for Treatment of Hematological Malignancies. Blood, 2014, 124, 3532-3532.	1.4	2
99	Gene Expression and Proteomic Profiling Predict Therapeutic Response to ABT-737 in Human and Mouse Models of Mantle Cell Lymphoma. Blood, 2008, 112, 608-608.	1.4	1
100	LITAF, a BCL6 Target Gene, Regulates Autophagia in B Cells and Is Essential for T-Cell Dependent Humoral Responses. Blood, 2011, 118, 1391-1391.	1.4	1
101	NIK Is Involved In the Activation of the Classical and Alternative NF-ÎºB Pathways In Diffuse Large B Cell Lymphoma. Blood, 2010, 116, 3099-3099.	1.4	1
102	Splenic Marginal Zone Lymphoma Shows a Distinct Pattern of DNA Copy Number Aberrations That Correlates with Tumor Characteristics and Predicts Disease Outcome.. Blood, 2006, 108, 2422-2422.	1.4	0
103	Identification of LMO2 Transcriptome and Interactome in Diffuse Large B-Cell Lymphoma by Integrated Experimental and Computational Approach. Blood, 2011, 118, 438-438.	1.4	0
104	Preclinical Activity of LBH589 Alone or in Combination with Chemotherapy in a Xenogeneic Mouse Model of Human Acute Lymphoblastic Leukemia. Blood, 2011, 118, 1520-1520.	1.4	0
105	Homeobox NKX2-3 Is Over-Expressed in Human B-Cell Lymphomas and Drives Marginal Zone B-Cell Lymphomagenesis in Mice. Blood, 2011, 118, 260-260.	1.4	0
106	Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes. Blood, 2013, 122, 77-77.	1.4	0